Loading
Maxcyte, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Aug 2025.
Maxcyte, Inc.: what insiders have been doing
Headquartered in Rockville, United States, Maxcyte, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 9 insiders have disclosed 9 filings since 18 October 2025.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €7,188. Biggest ticket of the year: €7,188, sold by Swirsky Douglas J and made public on 19 March 2026.
Filings reach the SEC (Form 4) feed a median of 5 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
With 9 filings in twelve months, the company is quieter than the median of 19 filings across the 5,816 companies we follow on the same exchange. The full history, which starts in 2021, counts 9 purchases against 8 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 33.0 m USD and net income at -44.6 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
95
Thresholds
n/a
Buy Volume
€21M
9 ops. · all time
Sell Volume
€18M
8 ops. · all time
Who traded when
BuySaleDouglas J. Swirsky1 buy2 sales
David I. Sandoval2 sales
Ali Soleymannezhad1 sale
Maher Masoud1 buy
Rekha Hemrajani1 sale
Richard Douglas1 buy
+2 other insiders
Since the insiders bought
- -6.4%Entry US$1.41 · Close at T+365 US$1.32
- -6.4%Entry US$1.41 · Close at T+365 US$1.32
- -6.4%Entry US$1.41 · Close at T+365 US$1.32
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,653 of 24,158 companies
29.8
score / 100
Value7
Quality52
FCF yld-27%
Earn yld-33%
EV/EBITDA·
ROE-20%
Gross mgn81%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.96
Analyst consensus
4 analysts1.33/5
US$2.43Target US$4.11(+326%)US$5.00
Income statement
RevenueUS$33M
Gross profitUS$26.8M81% margin
EBITDA-US$40.1M-122% margin
Net income-US$44.6M-114.8% margin
Valuation
PER (forward)-3.9x
P/Book0.6x
Beta1.49
Balance sheet & cash
Market capUS$99.5M
Total debtUS$17.9M
Free Cash Flow-US$36.2M
Debt / Equity11%
Profitability & ownership
ROE-20.4%
ROA-10.6%
% insiders1.8%
% institutions61.7%
Last declaration on 22 June 2026
Declarations95 total
30,421 sharesCommon StockSEC:0000905148-26-003054:0
30,421 sharesCommon StockSEC:0000905148-26-003049:0
30,421 sharesCommon StockSEC:0000905148-26-003050:0
30,421 sharesCommon StockSEC:0000905148-26-003051:0
30,421 sharesCommon StockSEC:0000905148-26-003053:0
30,421 sharesCommon StockSEC:0000905148-26-003052:0
187,500 shares0Common StockSEC:0000905148-26-001718:0
300,000 shares0Common StockSEC:0000905148-26-001480:0
10,142 shares@ US$0.8158.7% of flowCommon StockSEC:0000905148-26-001397:0
10,684 shares@ US$2.0945100.0% of flowCommon StockSEC:0000905148-25-003155:0
80,000 shares@ US$1.38815.5% of flowCommon StockSEC:0000905148-25-002874:0
Canonical exit: 11 Nov 2025 (T+90)
50,000 shares@ US$1.2966.8% of flowCommon StockSEC:0000905148-25-002877:0
Canonical exit: 11 Nov 2025 (T+90)
75,000 shares@ US$1.372233.0% of flowCommon StockSEC:0000905148-25-002876:0
Canonical exit: 11 Nov 2025 (T+90)
100,000 shares@ US$1.372297.2% of flowCommon StockSEC:0000905148-25-002875:0
Canonical exit: 11 Nov 2025 (T+90)
50,000 shares@ US$1.29100.0% of flowCommon StockSEC:0000905148-25-002873:0
Canonical exit: 11 Nov 2025 (T+90)
29,210 shares0Common StockSEC:0000905148-25-002235:0
29,210 shares0Common StockSEC:0000905148-25-002234:0
29,210 shares0Common StockSEC:0000905148-25-002233:0
29,210 shares0Common StockSEC:0000905148-25-002231:0
29,210 shares0Common StockSEC:0000905148-25-002230:0
29,210 shares0Common StockSEC:0000905148-25-002228:0
29,210 shares0Common StockSEC:0000905148-25-002232:0
29,210 shares0Common StockSEC:0000905148-25-002229:0
353 shares@ US$3.17934.9% of flowCommon StockSEC:0000905148-25-000985:0
6,939 shares@ US$3.179324.5% of flowCommon StockSEC:0000905148-25-000984:0
25 of 95 declarations
About Maxcyte, Inc.
MaxCyte, Inc. (ticker: MXCT) is a U.S.-based company listed on the NASDAQ in the United States and focused on cell engineering and non-viral transfection technologies. Founded in 1998 and operational since 1999, the company was built around its proprietary Flow Electroporation® technology, designed to modify human cells efficiently, reproducibly, and with low cytotoxicity. MaxCyte’s current headquarters is in Rockville, Maryland, in the I-270 biotech corridor. ([maxcyte.com](https://maxcyte.com/about-us/company-history/?utm_source=openai))
MaxCyte’s business model centers on its ExPERT™ platform, commercially launched in 2019, which includes several laboratory and development instruments such as ATx™, STx™, GTx™, and VLx™, along with proprietary processing assemblies, disposables, and software protocols. The company also provides scientific and regulatory support to customers developing cell and gene therapies, biologics, vaccines, and advanced research applications. This mix of instruments, consumables, and strategic platform licensing helps diversify revenue between core product sales and SPL program-related income. ([maxcyte.com](https://maxcyte.com/about-us/?utm_source=openai))
Read moreShow less
From a competitive standpoint, MaxCyte is positioned as a leading provider in non-viral cell engineering, a critical niche for biotech companies seeking to industrialize cell modification without relying on viral vectors. Its edge comes from the performance of its technology, its flexibility across cell types, and the regulatory credibility it has built over decades of commercialization and customer relationships in biopharma. The company also has an international footprint, with commercial relationships and operations spanning the United States, the United Kingdom, and broader global research and biomanufacturing markets. ([maxcyte.com](https://maxcyte.com/about-us/?utm_source=openai))
Recent highlights include MaxCyte’s May 12, 2026 first-quarter earnings release, in which it reported total revenue of $9.7 million and reaffirmed full-year 2026 guidance of $30-32 million. The company also authorized a $10 million share repurchase program. Earlier, in January 2025, MaxCyte acquired SeQure Dx to expand its offering into on-target and off-target editing assessment for cell and gene therapies, reinforcing its strategy of broadening the technology stack around advanced cell therapy workflows. For investors, MXCT remains a health-tech platform story with long-term exposure to structural growth in cell therapies, but also with monetization still in an early-to-mid stage of development. ([investors.maxcyte.com](https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-reports-first-quarter-2026-financial-results-and?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
